Cancer Institute And Hospital, Chinese Academy Of Medical Sciences

This early-phase study tests an inhaled mRNA vaccine called BMD006 for people with advanced lung cancer or solid tumors that have spread to the lungs. The vaccine is designed to train the immune system to attack tumor-related proteins. About 83 participants who have exhausted sta…

This study tests whether adding the targeted drug anlotinib to whole-brain radiation helps control brain tumors better than radiation alone in people with small cell lung cancer that has spread to the brain. About 134 participants will be randomly assigned to one of two groups. T…

This study tests whether a new drug, Trastuzumab rezetecan (SHR-A1811), works better than standard chemotherapy for people with HER2-Low breast cancer that has spread and is causing severe organ problems (visceral crisis). About 184 adults aged 18-75 will receive the drug every t…

This early-stage study tests a new drug called CREPT-618 in about 13 adults with advanced liver cancer that has not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look at how the drug moves through the b…

This early-phase study tests a new treatment called Meta10-TIL for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in the lab to better attack cancer. The main goal is to check sa…

This study is testing a new way of giving radiation before surgery for a rare type of cancer called retroperitoneal sarcoma. The goal is to see if this approach is safe and reduces complications during and after surgery. About 50 adults with this cancer will receive focused radia…

This study tests a new type of radiation therapy for prostate cancer that uses an MRI machine to guide the beam. It aims to deliver high doses of radiation more precisely, reducing damage to healthy tissue and side effects. The trial includes 50 men with either localized or limit…

This study tests two drugs, fuzuloparib and apatinib, given before surgery to people with advanced ovarian cancer that has a specific gene change called HRD. The goal is to shrink tumors enough for complete removal and avoid chemotherapy. About 48 participants will take these pil…

This study looks at whether adding immunotherapy or targeted drugs to standard chemoradiotherapy can help people with esophageal or esophagogastric junction cancer live longer. It involves 2,000 adults with stage I to IVa cancer who are not able to have surgery. The goal is to fi…

This study tests whether adding the drug ivonescimab to standard chemotherapy can shrink liver tumors from colorectal cancer that cannot be removed with surgery. About 40 adults will receive the combination every 3 weeks for up to 8 cycles. The goal is to see if the tumors become…

This study tests whether a precise, adaptive radiation boost can reduce side effects and maintain cancer control for people with prostate or bladder cancer. About 60 participants will receive the treatment on a special MRI-guided machine. Researchers will track side effects, qual…

This study tests a new combination of drugs for people with advanced stomach or gastroesophageal junction cancer that has not responded to initial treatment, including immunotherapy. About 60 participants will receive either a two-drug or three-drug regimen to see if it can slow …

This study tests a combination of an immunotherapy drug (adebrelimab) and three chemotherapy drugs given before and after surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can eliminate all cancer cells at th…

This study tests whether a new drug called Telpegfilgrastim, given as a single shot, works better than the standard daily Filgrastim to prevent low white blood cell counts (neutropenia) in children and young adults aged 6-24 with solid tumors. About 132 participants will receive …

This study tests whether adding an experimental immunotherapy (QL1706) to standard chemoradiation can help control locally advanced cervical cancer. About 30 women with stage III or IVA cervical cancer will receive the combination treatment. The goal is to see if it improves how …

This early-phase study tests an experimental therapy called V001 Injection, which creates cancer-fighting cells directly inside the body. It is for 50 adults with advanced blood or solid cancers that have not responded to standard treatments. The main goals are to check safety, f…

This study tests a combination of drugs (liposomal mitoxantrone, capecitabine, and anlotinib) in children, adolescents, and young adults aged 6 to 24 whose solid tumors have returned or not responded to treatment. The goal is to see if this combo can shrink tumors or stop them fr…

This early-stage study tests a new treatment for men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The treatment uses specially engineered natural killer (NK) cells from healthy donors to target and kill cancer c…

This study tests a new treatment called LK101, given together with standard immunotherapy drugs, for people with advanced lung cancer that has not responded to previous treatments. The goal is to see if the combination is safe and can shrink tumors. About 60 adults with non-small…

This study is for people who have had surgery for biliary tract cancer. It uses a special test called MiniPDX to see which chemotherapy drugs might work best for each person. The goal is to see if this personalized approach can help prevent the cancer from coming back. About 204 …

This study tests a mix of three drugs (nimotuzumab, toripalimab, and chemotherapy) as a first treatment for people whose nasopharyngeal cancer has come back or spread. About 30 adults with EGFR-positive tumors will receive the combination to see if it shrinks tumors and delays pr…

This study tests a combination of two drugs, low-dose cytarabine and thalidomide, in 50 adults with untreated Langerhans cell histiocytosis (LCH), a rare disease where immune cells build up and damage tissues. The goal is to see if this treatment can stop the disease from getting…

This early-stage study tests a single injection of umbilical cord blood cells (XJ-MK-002) in 16 adults aged 18-75 who have low platelets from cancer therapy. The main goal is to check safety and find the best dose. Researchers will monitor side effects and platelet counts for 28 …

This early study tests a new treatment called GC511B for adults with a type of lung cancer that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR T cells) to target a protein called DLL3 on cancer cells. The main goals a…

This early-stage trial tests a new cell therapy (Anti-PSMA CAR NK cells) in 10 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to check safety and side effects, not to cure the disease. Participants must ha…

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from returning. About 70 adults who have had their tumor removed will receive the combination for up to …

This study looks at how well the drug tislelizumab works when given before surgery for people with a specific genetic type of stage II-III colorectal cancer (dMMR/MSI-H). About 30 participants will receive three cycles of the drug, then have surgery to remove the tumor. Researche…

This study tests whether customizing follow-up treatments—like radiation, surgery, or stronger drugs—based on how well the tumor shrinks after initial therapy can help people with advanced breast cancer live longer without the disease getting worse. About 157 women with cancer th…

This study tests whether giving a drug called anlotinib along with radiation therapy before surgery can help people with soft tissue sarcoma in the arms, legs, or trunk. About 30 adults will receive this combination to see if it reduces major wound problems after surgery and impr…

This study tests a new treatment for advanced ovarian cancer patients who have a large amount of fluid in their belly (ascites) and have not responded to standard therapies. The treatment involves injecting specially activated immune cells (SK-NK cells) directly into the abdomen …

This study tests whether adding immune checkpoint inhibitors to standard chemotherapy before surgery can better shrink or eliminate tumors in people with locally advanced colorectal cancer. About 170 adults aged 18 to 75 with stage II/III colorectal cancer will be randomly assign…

This study tests whether a combination of lenalidomide and dexamethasone can control Rosai-Dorfman disease, a rare disorder where immune cells build up and cause lumps. About 40 adults aged 18 to 80 who are newly diagnosed or have not responded to prior treatment will receive the…

This study tests whether combining a liver-directed procedure (TACE) with two immunotherapy drugs (atezolizumab and bevacizumab) before surgery can eliminate or shrink tumors in people with high-risk liver cancer. About 30 adults with resectable liver cancer and features that rai…

This study tests whether combining radiation with an immunotherapy drug (sintilimab) works better than a standard procedure (TACE) to keep liver cancer from returning after surgery. It includes 286 adults whose tumors were removed but had narrow margins and high-risk features. Th…

This study tests a combination of two drugs (golidocitinib and a PD-1 inhibitor) as maintenance treatment for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combo can delay cancer growth or improve survival. About 20 a…

This study tests whether a special PET scan (68Ga-CTR-FAPI) can help surgeons remove medullary thyroid cancer more precisely. About 150 newly diagnosed patients will be randomly assigned to have surgery guided by this scan or by standard methods. The goal is to see if the scan le…

This study aims to find the best treatment before surgery for esophageal cancer. It compares chemotherapy, chemoradiation, targeted therapy, and immunotherapy in 2000 adults with stage I-IVa disease. The goal is to improve survival and reduce side effects.

This study tests whether the immunotherapy drug tislelizumab, given after surgery, can help prevent early-stage lung cancer from coming back in people with high-risk features. About 108 adults with stage I non-small cell lung cancer that is 2-4 cm and has certain high-risk signs …

This study is testing a new type of PET/CT scan that uses a special tracer called Al18F-octreotide to find tumors that have SSTR proteins on their surface. The goal is to see how accurate this scan is at detecting these tumors. About 400 people with known or suspected SSTR-positi…

This study is testing a new, non-invasive urine test that looks for a protein called CREPT in cells shed from the bladder. The goal is to see if this test can accurately detect bladder cancer early and monitor for its return after treatment, without needing a painful scope proced…

This study tests a drug called romiplostim N01 in children and young adults (ages 6-24) with cancer who have low platelets from chemotherapy. The goal is to see if weekly injections can safely raise platelet counts and reduce bleeding risk. About 50 participants will receive the …

This study watches 500 lung cancer patients who received immunotherapy before any other treatment. Researchers want to see if removing the whole lung or just part of it leads to better outcomes, and whether surgery is better than other treatments like radiation. The goal is to le…

This study is looking at whether proteins in urine can help doctors predict how well pre-surgery treatment works for people with locally advanced colorectal cancer. Researchers will collect urine samples from 400 patients before and after treatment and use advanced technology to …

This study is collecting long-term survival information from 109 people with advanced squamous non-small cell lung cancer who previously received tislelizumab combined with chemotherapy in the RATIONALE-307 trial. The goal is to better understand the lasting benefits of this immu…